Ex parte RINK et al. - Page 8




          Appeal No. 94-2592                                                          
          Application 07/707,265                                                      

          unpredictable, then it would not have been reasonable for one               
          of ordinary skill in the art to expect success in producing                 
          either one.                                                                 
                         Rejection under 37 CFR § 1.196(b)                            
               Under the provisions of 37 CFR § 1.196(b) we make the                  
          following new ground of rejection.                                          
               Claims 31 through 33 are rejected under 35 U.S.C. § 112,               
          second paragraph, for failing to particularly point out and                 
          distinctly claim the subject matter which the appellants                    
          regard as the invention.                                                    
               Claims 31 through 33 are confusing and misdescriptive in               
          the recitation of an eglin compound having the “amino acid                  
          sequence: N-acetyl-Thr. . . .”  Since the “N-acetyl” is not an              
          amino acid, it is not clear whether the appellants intend to                
          claim just the eglin amino acid sequence or an “N-acetylated                
          eglin.”  An amendment inserting “N-acetylated” between                      
          “following” and “amino” on line 2 of claim 31 would obviate                 
          this rejection.                                                             
               A similar problem exists in withdrawn claim 34.  Since                 
          the DNA sequence in paragraph a) encodes “said eglin                        
          compound,” it is not clear whether the appellants intend to                 

                                          8                                           





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  Next 

Last modified: November 3, 2007